ALGETA ASA | 18,738 Euro | -0,003 -0,02 % | |
| WKN: A0MNGH ISIN: NO0010239437 Ticker-Symbol: GJ9 | Frankfurt | 25.05.12 | 18:05 Uhr |
Branche GesundheitswesenAktienmarkt OMX Oslo 20 |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 16.05. | Algeta ASA: Updated survival results from phase III trial of Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) to be presented as Late-Breaking Abstract at ASCO 2012 | 41 | Thomson Reuters ONE | |
| Not intended for US media  Oslo, Norway, 16 May 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that further data from the... Mehr lesen zu: Algeta ASA: Updated survival results from phase III trial of Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) to be presented as Late-Breaking Abstract at ASCO 2012 | ||||
| 14.05. | Algeta ASA: Algeta to Present at Forthcoming Life Sciences Investor Conferences | 40 | Thomson Reuters ONE | |
| Not intended for US media Oslo, Norway, 14 May 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management... Mehr lesen zu: Algeta ASA: Algeta to Present at Forthcoming Life Sciences Investor Conferences | ||||
| 03.05. | Algeta ASA: CORRECTION: Algeta reports results for the first quarter 2012 | 14 | Thomson Reuters ONE | |
| This is a correction of the announcement from 07:00 03.05.2012 CEST. Reason for the correction: wrong pin codes for the conference call. Please below for correct pin codes. Not intended for US media... Mehr lesen zu: Algeta ASA: CORRECTION: Algeta reports results for the first quarter 2012 | ||||
| 03.05. | Algeta ASA: Algeta reports results for the first quarter 2012 | 57 | Thomson Reuters ONE | |
| Not intended for US media Oslo, Norway, 3 May 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its results for the first quarter... Mehr lesen zu: Algeta ASA: Algeta reports results for the first quarter 2012 | ||||
| 30.04. | Algeta ASA: Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody | 90 | Thomson Reuters ONE | |
| Not intended for US media Oslo, Norway, 30 April 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that its research collaboration... Mehr lesen zu: Algeta ASA: Algeta and Sanofi extend research collaboration evaluating thorium-conjugated tumor-targeting antibody | ||||
| 23.04. | Algeta ASA: Algeta schedules first quarter 2012 results presentation, webcast and conference call | 49 | Thomson Reuters ONE | |
| Oslo, Norway, 23 April 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its first quarter 2012 results on Thursday, 3 May... Mehr lesen zu: Algeta ASA: Algeta schedules first quarter 2012 results presentation, webcast and conference call | ||||
| 19.04. | Algeta ASA: Annual General Meeting held in Algeta ASA | 50 | Thomson Reuters ONE | |
| Oslo, Norway, 19 April 2012 - Algeta ASA announces that the Annual General Meeting in Algeta ASA was held today, and all items in the notice for the general meeting were resolved in accordance with... Mehr lesen zu: Algeta ASA: Annual General Meeting held in Algeta ASA | ||||
| 12.04. | Algeta ASA: Algeta exercises option to co-promote Alpharadin in the United States | 66 | Thomson Reuters ONE | |
| Conference call will be held today at 1pm CET, 12pm UK & 7am Eastern Oslo, Norway, 12 April 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics... Mehr lesen zu: Algeta ASA: Algeta exercises option to co-promote Alpharadin in the United States | ||||
| 29.03. | Algeta ASA: Algeta ASA - Notice of Annual General Meeting 2012 | 35 | Thomson Reuters ONE | |
| The shareholders in Algeta ASA are invited to attend the Annual General Meeting to be held on Thursday 19 April 2012 at 17.00 hrs in Algeta ASA's premises, Kjelsåsveien 172A (first floor) Oslo. Please... Mehr lesen zu: Algeta ASA: Algeta ASA - Notice of Annual General Meeting 2012 | ||||
| 15.03. | Algeta ASA: Algeta to Present at Forthcoming Life Sciences Investor Conferences | 47 | Thomson Reuters ONE | |
| Oslo, Norway, 15 March 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and investor relations... Mehr lesen zu: Algeta ASA: Algeta to Present at Forthcoming Life Sciences Investor Conferences | ||||
| 15.03. | Algeta ASA: Algeta to Present at Forthcoming Life Sciences ... | - | InvestEgate | |
| 22.02. | Algeta ASA: Algeta to Present at Forthcoming Life Sciences Investor Conferences | 32 | Thomson Reuters ONE | |
| Oslo, Norway, 22 February 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that senior management will participate in the following... Mehr lesen zu: Algeta ASA: Algeta to Present at Forthcoming Life Sciences Investor Conferences | ||||
| 22.02. | Algeta ASA: Algeta to Present at Forthcoming Life Sciences ... | - | InvestEgate | |
| 13.02. | Algeta ASA: 2011 Annual Report for Algeta ASA | 1 | InvestEgate | |
| 13.02. | Algeta ASA: 2011 Annual Report for Algeta ASA | 43 | Thomson Reuters ONE | |
| The Board of Directors of Algeta ASA has today approved the 2011 Annual Report. The 2011 Annual Report is attached hereto and is also available on www.algeta.com (http://www.algeta.com/). ###... Mehr lesen zu: Algeta ASA: 2011 Annual Report for Algeta ASA | ||||
| 10.02. | Algeta ASA: Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases | 87 | Thomson Reuters ONE | |
| Not intended for US media Oslo, Norway, 10 February 2012 - Algeta ASA (OSE: ALGETA) announces that the survival analysis has been completed on updated clinical data generated from the ALSYMPCA phase... Mehr lesen zu: Algeta ASA: Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases | ||||
| 10.02. | Algeta ASA: Analysis of updated ALSYMPCA phase III data con... | - | InvestEgate | |
| 09.02. | Algeta ASA: Algeta results for the fourth quarter 2011 and full year 2011 | 54 | Thomson Reuters ONE | |
| Oslo, Norway, 9 February 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its results for the fourth quarter and full year 2011.... Mehr lesen zu: Algeta ASA: Algeta results for the fourth quarter 2011 and full year 2011 | ||||
| 02.02. | Algeta ASA: Expanded Access Program for investigational drug Alpharadin (radium-223 chloride) initiated in the United States | 43 | Thomson Reuters ONE | |
| Not intended for US media Oslo, Norway, 2 February 2012 - Algeta ASA (OSE: ALGETA) announces that Bayer HealthCare Pharmaceuticals, Inc., with agreement from the US Food and Drug Administration... Mehr lesen zu: Algeta ASA: Expanded Access Program for investigational drug Alpharadin (radium-223 chloride) initiated in the United States | ||||
| 01.02. | Algeta ASA: Algeta schedules fourth quarter 2011 results presentation, webcast and conference call | 26 | Thomson Reuters ONE | |
| Oslo, Norway, 1 February 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its fourth quarter and full year 2011 results on... Mehr lesen zu: Algeta ASA: Algeta schedules fourth quarter 2011 results presentation, webcast and conference call | ||||
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
